 |
|
|
Professor E. J. Giamarellos-Bourboulis
Expert in Infectious Diseases and Immunology. Works at University of Athens, Medical School (Athens, Greece). He has designed, conducted and published clinical trials in the field of sepsis and of ventilator-associated pneumonia. He is intensively working both in basic science and translational research of immunotherapy of infectious diseases. He has published more than 150 peer-reviewed articles in this field.
Professor Steven Michael Opal
Chief of the infectious disease division at Memorial Hospital of Rhode Island and professor of medicine at the Alpert Medical School of Brown University, Providence, United States of America. He has served as the principal investigator for numerous worldwide, multi-center trials of adjuvant agents for severe sepsis, and has served on numerous data safety monitoring boards. Member of several professional societies including the Society of Critical Care Medicine, the International Cytokine Society, the Infectious Diseases Society of America and the International Endotoxin and Innate Immunity Society. He is the current chair of the International Sepsis Forum. He has published more than 190 peer-reviewed research articles and has edited several academic research journals as well as three textbooks on infectious diseases, endotoxin-mediated diseases and septic shock.
Professor Jordi Rello
Chief of the Critical Care Department, Hospital Vall d’Hebron, Barcelona, Spain. Trained on clinical epidemiology at Harvard Medical School. Awarded with Young Investigator Awards of the American College of Chest Physicians and co-recipient of the Emmanuel Wolinski Award (IDSA). He has published more than 250 articles and co-edited many books. He pioneered studies on prevention and control of device-related infections and in the therapy of VAP. He was president of the Catalonian Society of Critical Care, lead the CAPUCI and PIRO projects, former Chair of the Infection Section at the European Society of Intensive Care Medicine and current Head of the Working Group on Pneumonia and Director of Research Group of CIBERES. Prof. Rello is a consultant of pharmaceutical companies, serving in Editorial Boards of many Journals and advisory boards, as the ATS/IDSA Committee for VAP, HAP and HCAP guidelines. He promoted the 2009 H1N1 ESICM registry.
Dr. Philippe Eggimann
Dr Eggimann is Specialist in Intensive Care, Internal Medicine and Infectious Diseases at the Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. He has been awarded by several institutions and has been member of several groups: Fungal Group of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Board of the Swiss Sepsis Group, Scientific committee of FUNGINOS (Swiss fungal network), Swiss Society of Intensive Care Medicine and President its Congress. He is reviewer of several scientific journals: Lancet Infectious Diseases, AJRCCM, Clinical Infectious Diseases, Intensive Care Medicine, Critical Care, Chest, Infection, Infection Control and Hospital Epidemiology, and the European Journal of Clinical Microbiology and Infection. He has participated in several clinical and epidemiological studies in sepsis and nosocomial infections and he is author of numerous publications and chapters of medical books.
Prof. Dr. med. Michael Tamm
Michael Tamm studied medicine with a doctorate from the University of Basel. In 1991 he gained the specialist title in Internal Medicine. Michael Tamm spent a year in the United Kingdom in the Laboratory of Respiratory Physiology and Transplant Unit Papworth Hospital, Cambridge. Back in Basel he obtained the specialist title in pneumology (FMH). In 1999 Professor Tamm went to Sydney, Australia, as visiting Professor at the Institute of Respiratory Medicine. In the year 2002 he became head of the Clinic of Pneumology and Pulmonary Cell Research at the University Hospital Basel. He published more than 130 peer reviewed articles. His clinic and research laboratory are active in clinical and basic research.
Prof. Dr. med. Winfried V. Kern
Winfried Kern studied medicine in Bordeaux, Erlangen-Nürnberg and Heidelberg. Professor Kern is a specialist in Internal Medicine, Clinical Infectiology as well as Travel Medicine. His occupational career brought him to South Sudan, and the USA where he worked in San Francisco and Providence/Rhode Island.
Before he was appointed to a professorship for Internal Medicine at the University of Freiburg, he was head of the Infectiology and Clinical Immunology Unit in Ulm.
He is now head of the Infectiology Department of the University Hospital Freiburg.
Professor Kerns main research interests are infections in combination with immuno- deficiencies, mechanisms and clinical epidemiology of infections caused by multi-resistant bacteria and new rapid diagnostics tests.
Paul M. Tulkens (MD, PhD)
Paul M. Tulkens (MD, PhD) started his scientific career as a cell biologist and biochemist working in the laboratory of Prof. C. de Duve, Nobel Laureate, where he made significant contributions to our understanding of membrane movements during endocytosis, including receptor recycling, and in the development of models of acquired lysosomal storage disorders. He then moved to the study of the cellular and renal toxicity of aminoglycoside antibiotics, the mechanism of which he greatly contributed to decipher (from lysosomal alterations to apoptosis and cell necrosis) and for which he pioneered in reducing the clinical impact by promoting (and running the early clinical trials) of the now widely used once-daily dosing approach. From then on, he expanded his studies on antibiotics (macrolides, fluroquinolones) and intracellular infections (mainly S. aureus but more recently also P. aeruginosa). He also developed the science of pharmacodynamics and pharmacokinetics for optimising the use of antibiotics. He was amongst the founding members and is past President of the International Society of Antiinfective Pharmacology. Until 2010, he was full professor of Pharmacology and Drug Development at the French speaking Catholic University of Louvain (Brussels, Belgium) and professor of Human Biochemistry and Biochemical Pathology at the University of Mons (Mons, Belgium). He has published more than 230 scientific papers and continues, with his laboratory, to develop basic and applied approaches to the study of antibiotics and bacterial infections.
Prof. Dr. Hans Hengartner
Hans Hengartner studied biochemistry and molecular biology at ETH Zurich and holds a doctorate in natural sciences from ETH Zurich. He is currently Co-Director of the Institute for Experimental Immunology at the University Hospital of Zurich. He is also ordinary professor for immunology at the medical faculty of the University of Zurich and at the Department of biology of ETH Zurich. From 2000 to 2005 Hans Hengartner was Head of the Department of Biology at ETH Zurich.
Prof. Dr. med. , Dr. rer. nat. Jürgen Heesemann
Jürgen Heesemann studied chemistry at the University of Hamburg and Human Medicine at the University of Göttingen. He gained his doctorate as Dr. rer. nat. in the Faculty of Physical Chemistry and his Dr. med. qualification in the Faculty of Electrophysiology at the University of Göttingen. He is currently Professor of Bacteriology and Director of the Max von Pettenkofer Institute for Hygiene and Medical Microbiology at the University of Munich. He is also a member of the Council of the Centre for Infection Research at the University of Würz-burg, Chairman of the Committee of the Programme for the Promotion of Research and Teaching (Förderprogramm für Forschung und Lehre [FöFoLe]) of the Medical Faculty of the Ludwig Maximilians University, Munich (since 1999) and President of the German Society for Hygiene and Microbiology (Deutsche Gesellschaft für Hygiene und Mikrobiologie [DGHM]).
Jürgen Heesemann has received a number of awards, including the Dr. Martini Prize Ham-burg, the Special Prize of the Robert Koch Foundation, the Main Prize of the DGHM Foundation and the Aronson Prize of the City of Berlin.
Prof. Peter JM Openshaw
Peter JM Openshaw was trained in Medicine at Guy’s Hospital and was awarded the Treasurer’s Gold Medal in Medicine. After SHO (Brompton, Turner-Warwick; Guy’s, Renal), and registrar posts (Hammersmith Hospital and Ealing), he became senior registrar then consultant physician at St Mary’s Hospital, Paddington.
He founded the Academic Department of Respiratory Medicine at the St Mary's Campus of Imperial College in 1988, which he now leads. He is also Head of the Respiratory Infections Section of the National Heart and Lung Institute, a Division of the Faculty of Medicine of Imperial College London. The department is dedicated to the research on the immunopathogenesis of pulmonary viral infection and obstructive lung disease. His work is funded by the Wellcome Trust and Medical Research Council, UK.
He teaches undergraduates and postgraduate students, lecturing on immunology, vaccination and lung diseases. He organised and chaired the RSV symposium (Oxford, September 2005), a biennial global conference of ~250 experts. He reviews regularly for Nature Medicine, Nature Immunology, Journal of Experimental Medicine, The Lancet, Vaccine, Journal of Immunology, Journal of Virology etc. He is a member of the Council of the British Society for Immunology and of the Wellcome Trust’s Tropical and Clinical funding committee. He was elected a Fellow of the Academy of Medical Sciences in 1999.
Prof. Dr. Andreas Peschel
Andreas Peschel studied Biology in Bochum and Tübingen in Germany and obtained a PhD degree in Microbiology. He held postdoctoral positions in the labs of Friedrich Götz in Tübingen and of Jos van Strijp in Utrecht (The Netherlands) between 1995 and 2000 focusing on Staphylococcus aureus host/pathogen interaction. He joined the Faculty of Biology in Tübingen 2000 as an Assistant Professor and moved to the Medical Microbiology and Hygiene Department as a Professor of Cellular and Molecular Microbiology in 2003. His lab studies staphylococcal infections with special interests in evasion of antimicrobial defense mechanisms, proinflammatory bacterial molecules, and cell wall-associated virulence factors. Andreas Peschel co-founded the Interfaculty Institute of Microbiology and Infection Medicine at the University of Tübingen (IMIT) in 2009. He coordinates the Graduate School for Infectious Diseases and Microbiology in Tübingen, heads the Microbial Pathogenicity branch of the German Association for General and Applied Microbiology (VAAM), and received several research awards such as the Principal Investigator Award of the German Society for Hygiene and Microbiology.
Paul Klenerman
Paul Klenerman trained in medicine in Cambridge and then Oxford, and specialised in infectious diseases. His PhD was with Rodney Phillips and Andrew McMichael in Oxford, on T cell responses to HIV, especially looking at the influence of escape mutants. He did a postdoc with Rolf Zinkernagel and Hans Hengartner in Zurich, looking at virus persistence in the LCMV model. Subsequently he returned to Oxford and since 1999 has been analysing immune responses to hepatitis C virus, including vaccine development. The lab also runs projects to analyse immune responses to CMV, parvoviruses and HIV. His work has been funded largely through the Wellcome Trust since 1992, most recently with a senior fellowship.
|
|
